olpasiran
olpasiran: sourced relationships with 1 company · 3 clinical trials tracked.
olpasiran evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could olpasiran → ARWR affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) Atherosclerotic cardiovascular disease with elevated lipopro… | Phase 3 |
Clinical Trial Registry Records (3)
A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
Primary endpoint: Change in NCP Volume from Baseline to Week 72
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
Primary endpoint: Time to CHD Death, Myocardial Infarction, or Urgent Coronary Revascularization, Whichever Occurs First
A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran (AMG 890) in Subjects With Elevated Lipoprotein(a)
Primary endpoint: Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36
Frequently asked questions
Which companies have sourced relationships with olpasiran?
olpasiran has dated SEC/FDA relationship records for ARROWHEAD PHARMACEUTICALS, INC..
How many clinical trials involve olpasiran?
BioSniper tracks 3 clinical trials involving olpasiran.